Treatment with infliximab for pediatric Crohn's disease: Nationwide survey of Japan
- 31 July 2016
- journal article
- research article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 32 (1) , 114-119
Abstract
Background and Aim Childhood‐onset inflammatory bowel disease (IBD) is characterized by extensive intestinal involvement and rapid early progression. Infliximab (IFX), cyclosporin (CYA), and tacrolimus (FK506) are increasingly used to treat pediatric IBD; however, their long‐term effects and adverse events have not been properly investigated in pediatric patients. The aim of this study was to characterize the effects of these biologics and immunomodulators on pediatric IBD patients in Japan. Additionally, we assessed IFX use in pediatric patients with Crohn's disease (CD). Methods A national survey of IFX, adalimumab, CYA, and FK506 use in pediatric IBD patients (< 17 years of age) was sent to 683 facilities in Japan from December 2012 to March 2013. Secondary questionnaires were sent to pediatric and adult practitioners with the aim of assessing the effectiveness and safety of IFX for pediatric CD patients. Results The response rate for the primary survey was 61.2% (N = 418). Among 871 pediatric CD patients, 284 (31.5%), 24, 4, and 15 received IFX (31.5%), adalimumab, CYA, and FK506, respectively, from 2000 to 2012. According to the secondary survey, extensive colitis (L3, Paris classification) was diagnosed in 69.4% of pediatric CD patients who received IFX. Regarding the effectiveness of IFX in this population, 54.7% (99/181) of patients were in remission, and 42.0% (76/181) were on maintenance therapy. However, 32.0% (58/181) of patients experienced adverse events, and one patient died of septic shock. Conclusions Infliximab is reasonably safe and effective in pediatric CD patients and should therefore be administered in refractory cases.Keywords
Funding Information
- Health and Labour Sciences
This publication has 29 references indexed in Scilit:
- Long-term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT-1 and -2 Extension StudiesInflammatory Bowel Diseases, 2012
- Role of Thiopurine and Anti-TNF Therapy in Lymphoma in Inflammatory Bowel DiseaseAmerican Journal of Gastroenterology, 2011
- Pediatric modification of the Montreal classification for inflammatory bowel diseaseInflammatory Bowel Diseases, 2011
- Inflammatory bowel disease in children: epidemiological analysis of the nationwide IBD registry in JapanJournal of Gastroenterology, 2010
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005
- Inflammatory Bowel Disease in Children and Adolescents: Recommendations for Diagnosis‐The Porto CriteriaJournal of Pediatric Gastroenterology and Nutrition, 2005
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Use of infliximab in the treatment of Crohn's disease in children and adolescentsThe Journal of Pediatrics, 2000
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseNew England Journal of Medicine, 1997
- Development and Validation of a Pediatric Crohnʼs Disease Activity IndexJournal of Pediatric Gastroenterology and Nutrition, 1991